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Recommendations for the design of therapeutic trials for
neonatal seizures
Janet S. Soul1, Ronit Pressler2, Marilee Allen3, Geraldine Boylan4, Heike Rabe5, Ron Portman6, Pollyanna Hardy7, Sarah Zohar8,
Klaus Romero9, Brian Tseng6, Varsha Bhatt-Mehta10, Cecil Hahn11, Scott Denne12, Stephane Auvin13, Alexander Vinks14, John Lantos15,
Neil Marlow16 and Jonathan M. Davis17 for the International Neonatal Consortium18
Although seizures have a higher incidence in neonates than any other age group and are associated with signiﬁcant mortality and
neurodevelopmental disability, treatment is largely guided by physician preference and tradition, due to a lack of data from well-
designed clinical trials. There is increasing interest in conducting trials of novel drugs to treat neonatal seizures, but the unique
characteristics of this disorder and patient population require special consideration with regard to trial design. The Critical Path
Institute formed a global working group of experts and key stakeholders from academia, the pharmaceutical industry, regulatory
agencies, neonatal nurse associations, and patient advocacy groups to develop consensus recommendations for design of clinical
trials to treat neonatal seizures. The broad expertise and perspectives of this group were invaluable in developing
recommendations addressing: (1) use of neonate-speciﬁc adaptive trial designs, (2) inclusion/exclusion criteria, (3) stratiﬁcation and
randomization, (4) statistical analysis, (5) safety monitoring, and (6) deﬁnitions of important outcomes. The guidelines are based on
available literature and expert consensus, pharmacokinetic analyses, ethical considerations, and parental concerns. These
recommendations will ultimately facilitate development of a Master Protocol and design of efﬁcient and successful drug trials to
improve the treatment and outcome for this highly vulnerable population.
Pediatric Research (2019) 85:943–954; https://doi.org/10.1038/s41390-018-0242-2
INTRODUCTION
Seizures are one of the most common neurologic emergencies in
neonates, arising in ~3/1000 term live births and are associated
with signiﬁcant mortality and neurodevelopmental disability.1 In
contrast to seizures in older children, most neonatal seizures result
from acute symptomatic etiologies rather than epilepsy. The most
common etiologies include neonatal encephalopathy caused by
hypoxic-ischemia (HIE), focal ischemia affecting one or more
vascular territories (stroke), intracranial hemorrhage, infection,
cerebral dysgenesis, and metabolic disturbances.2 Neonatal
seizures are a major challenge for clinicians because of
inconspicuous clinical presentation, variable electro-clinical corre-
lation, and poor response to antiseizure drugs (ASDs). Guidelines
for their management lack adequate evidence, due to a lack of
sufﬁcient randomized controlled trials.3–6 Phenobarbital is used
worldwide as a ﬁrst-line medication7 even though it is only
effective in < 40–60% of neonates,2,8 while second-line medica-
tions are often midazolam, phenytoin, or levetiracetam.2,7 No new
ASDs have been evaluated and licensed for use in neonates,
resulting in the off-label use of drugs that have been tested only in
older children and adults.9,10 This practice carries considerable risk
to neonates.11,12 Drug trials in neonates pose major ethical
dilemmas: balancing the potential risks and beneﬁts of research
against harm from inadequately studied treatments, leading to
potentially effective treatments being withheld for lack of
evidence.12 Drug development is also hampered by logistical
challenges.13,14 There is an urgent need for novel drug develop-
ment programs that incorporate developmental factors, and for
prospective, randomized, controlled trials to test the safety and
efﬁcacy of new ASDs in neonates.
The International Neonatal Consortium (INC) was formed by the
Critical Path Institute (C-Path), an independent, non-proﬁt
organization dedicated to accelerating the pace and reducing
the costs of medical product development. The seizure working
group of INC consists of key stakeholders from research
institutions, the pharmaceutical industry, regulatory agencies,
nursing groups, patient advocacy, and other organizations to
develop guidelines/consensus recommendations for clinical trial
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design for treatment of neonatal seizures (Fig. 1). The inclusion of
broad expertise and perspectives in this international group of
experts resulted in a uniquely comprehensive set of recommen-
dations for neonatal seizure trial design.
A modiﬁed Delphi process15 was applied to develop the
recommendations. Key areas for recommendations were agreed.
Further topics were added from relevant guidance documents by
regulatory authorities. Statements for the recommendations were
formulated around the agreed key areas, followed by an
iterative process of amendment and agreement until agreement
was reached among the working groups before stakeholders
provided further feedback and a ﬁnal consensus was reached
(Fig. 2).
This paper describes a synthesis of views expressed by
colleagues in EU and North America, which does not necessarily
apply to colleagues in other jurisdictions, e.g., some clinicians in
Japan thought video-EEG is not feasible for evaluating seizures.
Nevertheless, the goal of the stakeholders in writing these
recommendations is to ensure more successful and efﬁcient trials
of ASDs for this vulnerable population and, consequently, better
antiseizure treatments. These recommendations are the crticial
ﬁrst step towards drafting a Master Protocol template to evaluate
multiple ASDs or treatments in neonates, which is a priority for
many regulatory agencies.16
PROTOCOL DESIGN
Inclusion/exclusion criteria
ASD trials should include neonates with EEG-proven and/or high
suspicion of clinical seizures or neonates at high risk of seizures,
such as neonates with neonatal encephalopathy caused by HIE,
stroke, or intracranial hemorrhage (ICH). Neonates with clinical
seizures or high risk of seizures should be included to optimize
enrollment and randomization of neonates as early as possible in
the course of seizures, but ideally should be randomized only if
EEG-proven seizures occur. Trial designs should specify the
minimum seizure burden required for enrollment and randomiza-
tion (see Primary Outcome section), and receipt of pre-approved
ﬁrst-line ASD, if add-on design is used. The following criteria
should be considered:
Inclusion criteria
A. Age and weight criteria
1. Postmenstrual age less than 43+ 6/7 weeks, as older
infants have different seizure etiologies, seizure patho-
genesis, and hepatic/renal function, potentially affecting
drug efﬁcacy, safety, and/or drug metabolism and
elimination.
2. Preterm neonates should only be included in the
following circumstances:
a. Preterm neonates < 35 weeks’ gestation for Phase
1/2 studies only if sufﬁcient safety and
pharmacokinetic data (PK) data available in term
neonates.
b. Preterm neonates < 35 weeks’ gestation in Phase 3
only if safety and PK data available for preterm
neonates.
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c. No absolute birth weight or weight at trial entry
minimum required, although PK/PD of drug may
require a minimum weight.
B. Etiologies of neonatal seizures: Etiologies of neonatal
seizures include moderate to severe HIE, stroke, ICH,
infection, cerebral malformations, genetic causes, epilepsy
syndromes, and other more rare causes.2,17 Etiologies to
include in trials should be carefully considered based
on anticipated drug mode of action, as some drugs may
be indicated or contraindicated for speciﬁc genetic etiolo-
gies (e.g., KCNQ2/3, SCN2A). Additionally, systemic illness
(e.g., severe hepatic or renal dysfunction) and treatments
(e.g., hypothermia) associated with speciﬁc etiologies could
affect drug efﬁcacy, PK, or safety parameters signiﬁcantly.
Inclusion of single vs. multiple etiologies will have sub-
stantial effects on trial feasibility and time to completion,
and consideration of endpoints, such as PK, safety, and/or
efﬁcacy.
1. All etiologies (except metabolic etiologies) may be
appropriate to include in Phase 1/2 trials if PK and
safety are main endpoints. Inclusion of all etiologies in
early phase trials has the advantage of uncovering
exceptional efﬁcacy or safety outcomes for particular
etiologies.
2. Single etiology (e.g., HIE, or hemorrhagic/ischemic
etiology) trials may be the best choice for Phase 3 trials
testing drug efﬁcacy because subject homogeneity with
regard to seizure pathogenesis decreases confounders
when comparing treatment arms, although anticipated
variability in seizure burden and outcome (even for HIE-
only) will still need to be incorporated into the trial
design. Conversely, a Phase 3 trial aimed to test a drug’s
effectiveness for all neonatal seizures may include
multiple etiologies.
Exclusion criteria.
A. Excluded etiologies
1. Single etiology trial (e.g., HIE): other causes of seizures
such as known brain malformation, genetic disorder, and
major congenital malformation.
2. Multiple etiologies trial: both acute metabolic and inborn
errors of metabolism. Metabolic etiologies should be
excluded as seizure treatment is largely directed at
correcting the metabolic abnormality, whether acute
transient metabolic abnormality (e.g., abnormal calcium,
glucose, etc.) or inborn error of metabolism, rather than
ASDs. Subjects may need to be excluded after enroll-
ment, since etiology often cannot be conﬁrmed at time
of seizure onset.
B. ASD(s) already given (other than sedative drugs), per
speciﬁc trial design.
C. Renal failure: Deﬁned as anuria in the ﬁrst 24 h after birth,
for ASDs with largely renal excretion.
D. Hepatic failure. Hepatic dysfunction requires caution if the
ASD under study is predominantly metabolized by the liver
E. Drug clearance safety considerations; organ toxicity con-
tingent on drug clearance proﬁle relative to ontogeny of this
unique population.
F. Subjects in whom death seems imminent (hours to several
days), as assessed by the treating neonatologist, as early
death may preclude assessment of drug efﬁcacy, safety,
and/or pharmacokinetics.
G. Participation in other interventional trials, with speciﬁc
exceptions.18
H. Unlikely that parent/neonate can complete evaluation of all
follow-up trial endpoints
I. Previous, current, or planned treatment with speciﬁc drug(s),
based on speciﬁc interaction with ASD being tested.
Choice of comparator
The choice of a comparator for use in neonatal seizure treatment
trials is constrained by limitations related to ethical issues,
feasibility, and available efﬁcacy and safety data. There is a strong
consensus among clinicians, researchers, and parents that it is
ethically unacceptable to randomize neonates with seizures to
placebo-only treatment. Among the reasons cited were evidence
suggesting harm of ineffective treatment of neonatal seizures and
some evidence indicating (although not deﬁnitively establishing)
efﬁcacy of currently used drugs.8,19,20 There is also consensus that
it would be unethical to delay starting antiseizure treatment in a
trial (i.e., no drug for several hours). Placebos could be used to
evaluate a new ASD using an “add-on” method, keeping the
subjects on identical maintenance treatments with the standard
drug (e.g., phenobarbital), then adding a new ASD to one arm and
placebo to the other.
Phenobarbital is recommended as the comparator that should
be used in trials of new drugs for the following reasons:
A. Phenobarbital is the most common, standard drug used to
treat neonatal seizures as a ﬁrst-line drug in > 90% of tertiary
centers.21
B. There are relatively few drug interactions for phenobarbital
(except induction of hepatic cytochrome affecting metabolism)
compared with drugs such as phenytoin or lidocaine.22–26
C. Available data suggesting (but not deﬁnitively establishing)
the efﬁcacy of phenobarbital, although the one published
randomized trial was not designed to test superiority and
was limited by the crossover design.8
D. Phenobarbital has well-documented pharmacokinetics with
consistent absorption and elimination compared with other
drugs.22,23,27
E. There are no controlled data available with alternative ASDs.
Limitations in using phenobarbital as a comparator include lack
of deﬁnitive data for efﬁcacy of phenobarbital and concerns that
high doses of phenobarbital could induce neuronal apoptosis in
the neonatal brain.28 Phenobarbital should be used as a
comparator to assess efﬁcacy or pharmacodynamics, although
phenobarbital may not remain the comparator of choice if a new
drug is shown to be superior, or at least equivalent, to
phenobarbital.
Treatment arms
The choice of the number and type of treatment arms should be
guided primarily by the goals of the trial, keeping the following
points in mind.
1. Preliminary trials for testing PK may use one treatment arm,
as a control group may not be needed, but most other trials
must include a control arm.
2. Larger Phase 2 or 3 trials testing safety and efﬁcacy,
including trials with dose-ﬁnding design, require a compar-
ison group and stopping rules for an unacceptable safety
proﬁle. A control group allows attribution of adverse events
to drug vs. underlying disease, given the typical high
incidence of adverse events in critically ill neonates with
seizures. Similarly, the safety proﬁle of previously used drugs
may be known, but new therapies (e.g., hypothermia, new
non-seizure drugs) could affect the safety proﬁle of old and
new ASDs alike. Thus, trials of previously used ASDs may
require a control group to test the safety of these drugs
combined with newer therapies.
3. Phase 3 trials to establish efﬁcacy for neonatal seizures will
require a comparison group in a superiority designed trial as
a non-inferiority trial design is not possible, for the following
reasons. A superiority trial design is currently required for
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neonatal drug approval by the FDA. Superiority does not
require ﬁrst establishing that phenobarbital is efﬁcacious, if
phenobarbital is considered “standard” therapy. In principle,
efﬁcacy may be demonstrated by superiority or non-
inferiority trial designs; however, non-inferiority designs
are not currently an option for drug approval in neonates
because there is a lack of data from multiple neonatal
clinical trials (or placebo-controlled trials of phenobarbital)
required to set the margin of a non-inferiority trial.
Furthermore, a non-inferiority design would require a larger
sample size and phenobarbital would ﬁrst need to be shown
to be effective.29,30 For FDA approval, it is not acceptable to
conclude similar efﬁcacy with superior safety. For EMA
approval, a positive beneﬁt to risk ratio should be
demonstrated for Marketing Authorization. Randomized
comparative trials are recommended for approval. However,
recognizing the feasibility challenges of drug trials for
neonatal seizures, the use of a historical control group might
be acceptable for approval, provided there is pre-deﬁned
matching by age, condition, standard of care, and diagnostic
methods.
4. The use of three or more treatment arms is possible if two or
more drugs are being compared to a control. In this case, an
adaptive design to favor the safest and most effective drug
may be preferred.
Trial design
There are very few trial designs speciﬁcally developed for
neonates and even fewer for neonatal seizures. Neonate-speciﬁc
trial designs are being developed following the recent update of
ICH E11(R1) guideline in 2016, in which regulatory agencies
emphasized the need for extrapolation, simulation, and modeling,
and for innovative methodology in pediatric clinical trials.31 For
example, a uniﬁed approach for extrapolation and bridging
information was proposed for early phase pediatric studies using
different types of data sources to plan early phase clinical trials.32
All available information should be used to inform design of
neonatal seizure trials, including data available from off-label use
of ASDs and expert opinion, to optimize design for small sample
trials. All assumptions should be clearly stated, as emphasized by
the ICH E11(R1) guideline.31
In response to a call by the EU, three multidisciplinary groups are
developing dedicated methods for small sample trials (all phases)
under frequentist or Bayesian inference,33 which could be modiﬁed
and used for neonatal seizures. Bayesian inference-based designs
are well suited to neonatal ASD trials, as previous/current data and
expert opinion can be summarized in the prior distribution and
used for data analysis. Such innovative methodology with adaptive
design was applied in the NEMO dose-ﬁnding trial of bumetanide,
which included joint modeling of short-term safety and efﬁcacy,
but not long-term toxicities.34 As the trial was stopped early for
serious adverse effects without apparent evidence of efﬁcacy,
a novel design was developed for a subsequent early phase trial
of levetiracetam (NCT02229123).35 Data from these ongoing
trials (e.g., Boston bumetanide trial and levetiracetam trials) will
need to be incorporated into the design of future neonatal ASD
trials.
Endpoints. Endpoints must be clearly deﬁned, including end-
points for PK, safety, and/or efﬁcacy, depending on the trial phase
(early or late). Recommendations for primary and secondary
outcomes to measure drug efﬁcacy and safety are described in the
sections on Neonatal Seizure Outcome and Neurologic & Long-
term Outcome, and PK measurements in the section on Drug
Related Issues. A trial may employ a single endpoint, or two or
more endpoints, particularly for Phase 2 & 3 trials (either dual or
composite endpoints).
Dual endpoints may be employed in early phase trials, i.e., two
independent endpoints used together for modeling and analysis.
Clinically meaningful composite endpoints that are expected to
act in the same direction (e.g., seizure reduction and maintenance
of seizure freedom) may be employed to maximize efﬁciency of
drug testing. For composite endpoints, each endpoint should
represent a clinically meaningful efﬁcacy outcome of equal
importance, as for seizure reduction and maintenance of seizure
freedom. Composite endpoints may not be suitable for early
phase trials designed to test PK and safety, as ASD safety and PK
parameters are different types of endpoints with unequal
importance.
Choice of trial design
The trial design selected should use estimation methods (for
early phase exploratory trials) and provide the best evidence (for
Phase 2/3 randomized conﬁrmatory trials) with the fewest number
of neonates to maximize potential beneﬁt and minimize risk. As
such, adaptive trial designs integrating an interim analysis for
safety and/or efﬁcacy evaluation are increasingly accepted designs
that may provide these advantages.36
A. Adaptive design
Advantages of sequential/adaptive design:
1. Optimizes the number of included or randomized
subjects, which is important given the relatively limited
population of eligible neonates with seizures.
2. Maximizes the number of subjects included or rando-
mized to the most/more effective treatment, since data
analyzed sequentially during the trial beneﬁt subse-
quently enrolled subjects (e.g., prioritize treatments
based on optimal seizure reduction).
3. Trial stops as soon as pre-deﬁned efﬁcacy endpoints
have been adequately evaluated, e.g., reaching a pre-
deﬁned threshold of increased probability of seizure
reduction.
4. Can adapt one or more design variables, such as
treatment group assignment, sample size, dose selec-
tion, or even endpoint deﬁnition (based on interim
estimate of treatment effect), e.g., de-prioritize treat-
ments that miss the pre-deﬁned threshold for seizure
reduction probability.
Requirements to be speciﬁed before using an adaptive
design:
An adaptive design requires generation of initial assump-
tions based on all available data from published trials and
observational data. In addition, the stopping rules for these
designs depend on the deﬁnition and selection of the study
endpoints. This limitation regarding endpoints exists in part
because clinically meaningful reduction in neonatal seizure
burden as a primary endpoint has been deﬁned partly by
expert consensus rather than direct evidence of any beneﬁt
(s) of seizure reduction. In particular, the large variability in
seizure burden in neonates may make an adaptive design
based on endpoints or treatment assignment more prone to
error with small sample size. A limited sample size in an
adaptive design trial may also be too small to adequately
test some outcomes completely (e.g., safety and secondary
outcomes). Thus, early phase dose escalation studies might
need to stipulate a minimum number of subjects prior to
escalation if there are limited safety data available for the
drug being tested, which favors inclusion of a control arm.
Conﬁrmatory randomized trials that use a frequentist
approach require a priori consensus on the null hypothesis
for superiority testing (what constitutes adequate evidence
of a drug effect), which deﬁnes the upper and lower bounds
for the stopping rules.37–39 For conﬁrmatory trials using a
Bayesian approach, consensus is needed for the deﬁnition
of the threshold of the posterior probabilities for efﬁcacy
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parameters, such as a given increase in the probability of
neonatal seizure reduction.
B. Conventional (i.e., non-adaptive) trial design:
Conventional design may be appropriate for exploratory,
early phase trials if there is signiﬁcant uncertainty regarding
many of the initial assumptions, which limits generation of
critical aspects of an adaptive trial design.
C. Crossover design:
Crossover design is discouraged because it requires a
signiﬁcantly larger number of subjects to test most
outcomes (efﬁcacy, safety, PK/PD), and because there is
limited interpretation of all outcomes if majority of subjects
crossover, as is likely given high failure rate of current drugs
for neonatal seizures.
Randomization. A central, pre-deﬁned randomization strategy
should be employed for all Phase 2B or Phase 3 trials with two or
more treatment arms, taking into account stratiﬁcation considera-
tions to balance treatment arms (see below). Randomization
should occur as soon as possible after seizure onset, and within
24 h of seizure onset, to ensure that the study drug is tested prior
to natural resolution of seizures. Randomization assignment
should also take place as close as possible to the time of study
drug administration, as some stratiﬁcation covariates (e.g.,
hypothermia, severity of encephalopathy) may change between
time of enrollment and randomization.
Balancing treatment arms:
The randomization method should ensure balance across only
essential subject characteristics that can affect one or more
outcomes and that can be readily identiﬁed at enrollment. The
method of randomization (e.g., stratiﬁed block randomization or
minimization) should be considered according to the number of
variables selected. Subject characteristics to consider:
A. Seizure etiology and seizure severity would ideally be
balanced between treatment arms but are often impossible
to determine at the time of enrollment or randomization.
Instead, these can be pre-deﬁned subgroups, which are
adjusted for at the analysis stage (see Statistical Analysis
Plan). This may be particularly important for dose-ﬁnding
studies where the optimal dose may vary with seizure
severity.
B. Centers should be balanced whenever possible in multi-
center studies to account for center differences in popula-
tions and neonatal and neurological management.
C. Therapeutic hypothermia (TH) treatment may affect drug PK,
safety, and efﬁcacy, and is usually known at the time of
enrollment and randomization. It is important to balance the
treatment arms with regard to TH, due to limited numbers
of neonates with HIE not treated with TH.
D. Gestational age (GA) at birth is not essential because of the
lesser effect on outcomes compared with the characteristics
listed above (GA at birth can be pre-deﬁned and adjusted
for at the analysis stage, see Statistical Analysis Plan).
Masking (blinding). Investigators, treating clinicians, and subjects’
family members should all be masked to treatment assignment
for randomized trials with more than one treatment arm to
preserve integrity of trial conduct, data collection, and data
analysis. This is particularly important for trials of ASDs, since
natural variation in seizure burden over time could be falsely
attributed to treatment success or failure. The Data and Safety
Monitoring Board (DSMB) should be masked for the same reason,
although could be unmasked early if there are safety concerns or
the possibility of achieving a pre-deﬁned endpoint prior to study
completion.
Safety. Neonatal seizure treatment trials require safety monitor-
ing by an external DSMB with appropriate expertise, including
pediatric neurologists/neurophysiologists and neonatologists with
expertise in neonatal seizures and the seizure etiologies being
included in the trial, and a statistician with trial experience. This is
particularly important since adverse events of many kinds
(neurologic and non-neurologic) occur commonly in critically ill
neonates with seizures caused by asphyxia/HIE or other systemic
disorders (including serious adverse events such as death). The
frequent occurrence of adverse events means that a control arm is
essential to compare rates of adverse events for all but certain
early phase trials of drug PK. Adverse events and estimated rates
of those events should be deﬁned prior to trial commencement,
including events and laboratory values related to the underlying
condition(s) and study drug, given the possibility of the study drug
resulting in increased (rather than reduced) seizure burden. The
rate of adverse events may vary according to the population of
neonates being studied, seizure etiology, and study drug toxicities,
so needs to be deﬁned for each trial. Stopping rules for safety
outcomes should be separate from efﬁcacy or other primary
outcomes, including for dose-ﬁnding trials. The investigators and
DSMB should monitor adverse events closely throughout the
neonatal hospitalization. Serious adverse events such as death and
illnesses/injury leading to permanent disability should be
reviewed and reported immediately to the DSMB and governing
IRB(s), according to the deﬁnitions set out by the FDA/EMA/
NIH.40,41 Finally, long-term outcome should be included as both a
safety and efﬁcacy measure (see Section on Neurologic and Long-
term Outcome Measures).
Statistical plan, stopping rules and analyses.
A. Sample size considerations
The statistical approach should take into account the
sample size needed to evaluate primary and secondary
outcomes adequately, and employ pre-deﬁned endpoints
and analysis approach for all outcomes. If a frequentist
analysis plan is chosen, a clear deﬁnition and justiﬁcation of
the null and alternative hypothesis should be speciﬁed (e.g.,
H0: lack of difference in the proportion of controlled
seizures between treatment and control groups). Moreover,
the power and alpha parameters choices should be clearly
identiﬁed at trial initiation, typically, 1-β= 0.8, α= 0.05. Any
increase of alpha above 5% or decrease of power value
below 80% should be justiﬁed. If a Bayesian analysis plan is
chosen, prior distribution of the estimated parameters
should be clearly identiﬁed (e.g., expected probability of
seizure reduction for given treatment). The construction and
the prior distribution choice of parameters should be
explained and justiﬁed. A decision rule on how to categorize
a treatment win should also be pre-speciﬁed (e.g., targeted
increase in the probability of seizure reduction, given an
intervention), using expert opinion, trial data, or any other
source of available data.
Sample size for efﬁcacy trials should be deﬁned to detect a
clinically meaningful reduction in seizure burden (see
Section on Neonatal Seizure Outcome Measures), keeping
the follow points in mind:
1. Outcome measures likely exert the greatest inﬂuence on
sample size.42
2. Large variability in seizure burden in subjects affects
sample size signiﬁcantly and may not be accounted for
by randomization alone.
3. Given the challenges of enrolling sufﬁcient numbers of
eligible neonates with seizures, the feasibility of the
proposed sample size needs to be considered with
regard to available subjects, cost, and time to study
completion.
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B. Stopping rules
1. The plan for any interim analyses should be speciﬁed in
advance (e.g., interim analyses at given sample size
targets), together with stopping guidelines (e.g., stop-
ping at a given increase in the probability of seizure
control). Even planned interim analyses may require an
increase in sample size, which should be detailed in the
original design and statistical analysis plan, as possible.
2. Separate stopping rules are needed for safety and
efﬁcacy.
a. Stopping rules for safety should include continuous
interim analysis for safety monitoring based on
previously deﬁned distribution (not rate) of adverse
events in the enrolled population and according to
the predicted potential toxicities of the study drug
speciﬁc to neonates with the included seizure
etiologies.
b. Stopping rules for efﬁcacy should be deﬁned by
clinical investigators and the trial statistician (e.g.,
reaching a pre-deﬁned increase in the probability of
seizure reduction). However, it should be difﬁcult to
stop a trial early for efﬁcacy, due to the need to
analyze long-term assessments of safety and neuro-
developmental outcome.
3. Rare reasons for late or substantial changes to the
trial design or analysis plan could include major errors
in initial statistical assumptions, e.g., differences in
data distribution or model of seizure reduction.
This should be avoided whenever possible and will
require substantial changes to the statistical analysis
plan.
C. Statistical analysis plan
There are several issues speciﬁc to drug trials for neonatal
seizures that should be addressed in planning the statistical
analyses.
1. Severity of seizure burden is one of the most important
covariates (often the most important) that must be
considered in any analysis of drug response/efﬁcacy.
Currently, there is no universally accepted deﬁnition of
severity of seizure burden, which varies with seizure
etiology and patient population. Since seizure severity
currently cannot be determined reliably at time of
randomization, subjects cannot be stratiﬁed by seizure
severity. The statistical analysis plan will therefore
require modeling that includes subgroup analysis by
seizure severity at trial completion, as a pre-planned
post-hoc analysis for any early or late phase trials testing
dose response or efﬁcacy.
2. Seizure etiologies also may not be balanced among
treatment groups if more than one etiology is included,
since seizure etiology is often unknown at time of
enrollment or randomization. Instead, trial designs
should include a pre-planned post-hoc analysis to
determine whether treatment effect differs for different
seizure etiologies. Adjusting for these types of char-
acteristics in the analysis improves the precision of the
overall treatment effect (i.e., provides a smaller standard
error).
3. There are other potential clinical covariates that may
affect measurement of the efﬁcacy, safety, or PK of ASDs
in neonates, such as GA at birth, postmenstrual age at
randomization, weight, or factors speciﬁc to the drug
(e.g., renal or hepatic clearance), which should be
accounted for in the analysis plan.
NEONATAL SEIZURE OUTOME MEASURES
Introduction
Continuous video electroencephalography (cvEEG) is the gold
standard for seizure detection in neonates,43 as it is well
established that the clinical evaluation of seizures without cvEEG
conﬁrmation can lead to both over- and under-diagnosis.44
Continuous video-EEG monitoring is essential since subclinical
seizures occur in most neonates and as many as 16% have only
subclinical seizures,2 particularly those with severe encephalo-
pathy and/or receiving sedative medications. Both the FDA and
EMA recognize the incontrovertible data showing the superiority
of multichannel cvEEG monitoring for accurate detection of
neonatal seizures compared with reduced montage devices such
as aEEG, or EEG without video. Seizures are accurately detected
with high inter-rater reliability when read by pediatric neurophy-
siologists, who should be the readers for any ASD trial evaluating
drug response or efﬁcacy.45 Thus, multichannel (minimum 8-20
channels) cvEEG monitoring is needed for accurate detection of
seizures to determine drug response in neonatal seizure trials in
order to obtain regulatory approval from the FDA and EMA. The
measure of choice to assess drug efﬁcacy is neonatal seizure
burden measured in minutes of seizure activity per hour by
cvEEG.8,34,46,47
To establish a robust primary outcome measure for a clinical
trial of neonatal seizure treatment, we reviewed the available
literature regarding treatment of neonatal seizures and performed
an international survey of neonatologists, pediatric neurologists,
and other expert clinicians who treat neonatal seizures. The
literature review showed that a pre-treatment baseline period and
response to treatment were rarely deﬁned clearly, although an
80% reduction in seizure burden was the most commonly cited
desired drug response. Although the international survey yielded
variable opinions regarding the pre-treatment seizure burden that
should prompt treatment, an 80% reduction in seizure burden was
designated an optimal drug response. See “Supplemental
Appendix 1 (online)” for Literature Review and Results of
International Survey. As there is no current consensus on how
treatment efﬁcacy for neonatal seizures should be measured or
data that deﬁne what speciﬁc reduction in seizure burden
improves neurologic outcome, we propose the following:
Proposed neonatal seizure outcome measure
Seizure burden prior to treatment—the baseline period. A baseline
period is needed to establish entry criteria to a trial. A cumulative
electrographic seizure burden of at least 30 seconds/hour (sec/h)
during the baseline period is needed for a subject to be eligible for
randomization. Conﬁrmation of electrographic seizures by a local
or central neonatal EEG expert is required. Study drug adminis-
tration should start as soon as possible after the 30 sec/h of
seizure activity is conﬁrmed by the expert, ideally within 30 min
(maximum two hours) of the end of the last conﬁrmed
electrographic seizure, or with ongoing conﬁrmed electrographic
seizures. If study drug cannot be administered within two hours of
the last seizure, then study drug should not be administered
unless and until another 30 sec/h of seizure activity occurs. This is
necessary to avoid randomizing neonates whose seizures have
resolved spontaneously before administration of study drug.
Seizure Treatment Diagram outlines an example of a trial protocol
(Figure 3).
The primary seizure outcome measure. The primary outcome
measure in a late phase drug efﬁcacy trial should be the total
seizure burden (in minutes/hour) per subject in the response
period (i.e., continuous outcome measure) after study drug
administration. A period of ~30min following drug administration
is required for peak drug exposure, a time period which may need
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to be reduced or extended depending on the drug’s properties.
The response period should be deﬁned as a ≥ 2 h period following
the time of expected peak drug exposure. The comparison of
seizure burden/subject between treatment arms may need to be
adjusted for overall seizure burden, particularly if the severity of
seizure burden is not balanced among treatment groups (e.g., by
chance). The primary outcome may also be measured as the
reduction in seizure burden during the response period,
compared with a ≤ 2 h baseline period immediately prior to study
drug administration, if the baseline period is of adequate duration
in sufﬁcient numbers of subjects. An adequate baseline period is
more likely to be available in trials of second-line drugs or add-on
therapies.
For early phase dose-ﬁnding trials, a responder rate needs to be
deﬁned as a speciﬁc, clinically meaningful reduction in seizure
burden. In early phase trials, reduction in seizure burden during a
response period may be compared with the baseline period, but
will need to be adjusted for total seizure burden, given the
typically small sample size in early phase trials. For example, a
primary outcome could be a > 30% reduction in seizure burden in
neonates receiving study drug compared with control neonates
receiving standard treatment. A smaller reduction in seizure
burden may be considered appropriate for neonates with severe
seizures, such as status epilepticus.
Efﬁcacy of the study drug (or meaningful drug response for
early phase trials), should be demonstrated by a meaningful
reduction in seizure burden in the study drug group that is
statistically and clinically superior to that of the control
comparator group. Notably, the baseline period may be very
short for some subjects, and will likely have variable duration for
all subjects in a trial. Use of a control arm can mitigate the effect of
variable baseline periods and ﬂuctuating seizure burden, and
overall seizure burden can be used as a covariate in the analysis of
drug response or efﬁcacy. Drug response or efﬁcacy should also
be evaluated by the relationship between seizure reduction and
dose exposure, determined by measured drug levels and
population PK analysis.
Seizure recurrence is another outcome measure that may be
used as an equally important outcome measure, i.e., combined
with a reduction in seizure burden as a composite endpoint for a
primary outcome, or as a secondary outcome measure. The
recurrence of seizures is measured by total seizure burden from
the end of the deﬁned response period until 48 h after study drug
administration (i.e., 48 h for acute seizures from ischemic/
hemorrhagic etiologies, up to 72 h for other etiologies, e.g.,
infection, genetic/malformation). This is contingent on mainte-
nance of therapeutic levels of study drug (Fig. 3 Seizure Treatment
Diagram).48 Thus, cvEEG monitoring should be continued for at
least 48 h after study drug administration and at least 24 h after
the last conﬁrmed EEG seizure.
Finally, administration of rescue ASDs could be used as another
outcome measure of drug response or efﬁcacy, depending on
whether or not the trial protocol stipulates when and what doses
of ASDs can be administered by the treating clinicians. Adminis-
tration of rescue ASDs is clearly a less reliable outcome measure if
left to the discretion of treating clinicians than if rescue ASDs are
stipulated by the trial protocol. As for seizure recurrence as an
outcome measure, administration of rescue ASDs should be
reported only if there is maintenance of therapeutic levels of study
drug. Figure 3 is an example which would need to be adapted to a
given study drug and protocol.
NEUROLOGIC AND LONG-TERM OUTCOME MEASURES
Although the primary efﬁcacy outcome for trials of ASDs in neonates
is reduction of seizure burden, any medication that treats seizures
may also affect brain development and injury, and risk of later
epilepsy. Ideally, an effective and safe ASD would reduce the risk of
later epilepsy and neurologic disability. Seizures impair brain
function acutely and may exacerbate brain injury,19 so there may
be a signiﬁcant beneﬁt to reducing seizure burden. Some ASDs may
reduce the incidence or severity of later epilepsy, or have additional
neuroprotective effects on the brain which could improve long-term
outcome.49–53 Thus, demonstration of improved long-term neuro-
logic outcome, including reduced incidence of epilepsy, could be a
secondary outcome measure of drug efﬁcacy. Improved long-term
neurologic outcome should be a secondary (rather than primary)
outcome measure, largely because outcome is primarily determined
by seizure etiology, such as the severity and location of any neonatal
brain injury, brain malformation, or neurogenetic disorder. Thus any
measure of long-term neurologic outcome needs to be correlated
ﬁrst with seizure etiology, including imaging abnormalities.
Conversely, medications used in the neonatal period have the
potential to disrupt or adversely inﬂuence development of the
brain (e.g., via neuronal apoptosis) and other organs, which may
be dose dependent.52,53 Long-term safety is always an important
issue, but the dilemma of “How long is enough?” is a central issue
in all neonatal drug trials. For safety concerns, neonates involved
in drug trials should be closely monitored throughout the
neonatal period (i.e., to 30 days), as well as into infancy and
childhood, because some adverse (or beneﬁcial) effects may not
be detectable for years. Long-term follow up prolongs trial
duration and is expensive as it requires tracking, retention
strategies, and assessments of neurodevelopmental outcome.
Development is signiﬁcantly inﬂuenced by the child’s environ-
ment, which is a confounding variable. Sociodemographic data
should be collected at each time point. Nevertheless, the neonatol-
ogy literature has proven the importance of determining adverse
long-term outcomes of neonatal interventions.54,55 The lists of
secondary outcome measures below are organized by age of
assessment and the category of neurologic function or general health
Neonatal EEG
monitoring
ongoing
No electrographic
seizures
Continue to screen EEG
Secondary outcome:
Seizure recurrence, ASDs
within 48 h of study drug
adminstration
Primary outcome:
Seizure burden s/h in
response period
Predefined response
period, after
appropriate drug peak
exposure period
Exit study after 48 h if
no electrographic
seizures
Electrographic seizures
lasting ≥ 30 s/h during
baseline period
Randomization
Infusion of study drug
≤ 2 h (ideally ≤ 30 min)
from end of last
confirmed EEG seizure
Fig. 3 Seizure treatment diagram
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being measured. Many of these measures are speciﬁc to particular
countries or languages, so need to be adapted to local validated tools
(complicating comparison in multinational trials). Nevertheless, a
comprehensive assessment of neurodevelopmental outcome, later
seizures/epilepsy, and general health is needed to determine any
beneﬁcial or detrimental effect of ASDs tested in neonates.
Neonates
Neonatal clinical assessment: The best measures of nervous
system function involve neurologic examination and/or observa-
tion of a neonate’s behavior. Three standardized exams and one
standardized movement assessment (which all require speciﬁc
training) have been used to assess neurologic integrity, sensory
responses, and behavior in full-term neonates with brain injury.
Additional measures of brain function and structure that may be
affected by ASDs can be assessed prior to hospital discharge,
shown in Table 1.
Toddlers
For safety, adequate assessment of neurologic function requires
follow up for at least 18 months to two years, the earliest age at
which major neurodevelopmental disability can be reliably
determined. Cognition can be assessed more precisely at ≥ 3
years when cognitive and particularly language skills are more
complex (Table 2).
School-age children
More precise evaluation of cognitive and neuromotor function
beyond the major disabilities is best achieved at school age with
the use of standardized age-appropriate instruments. Although for
practical reasons drug approval and licensing may be determined
based on two-year (corrected age) outcomes, commitment for
post marketing surveillance for at least ﬁve years should be
considered. Processes can be put in place to maintain contact with
and trace families to minimize dropout, which could bias trial
results (Table 3).
DRUG RELATED ISSUES
Legislation in the EU and USA requires compulsory development
of age-appropriate formulations for neonates and children in the
development of new drugs. The aim is to support the develop-
ment of pediatric formulations, which enable neonates to have
access to safe, age-appropriate dosage forms. These dosage forms
should allow accurate and ﬂexible dose administration and should
contain only excipients which are known to be safe and effective
for the age of the child.
Further guidance on administration, dosing, and formulation,
bioanalytical requirements for drug and biomarker analysis for
population PK/PD studies, drug speciﬁc safety measures, per-
mitted or prohibited drug speciﬁc concomitant care and inter-
ventions for ASDs are similar to those for other neonatal drugs56
and thus not included in this paper, but are outlined in
Supplemental Appendix 2.
ETHICAL CONSIDERATIONS OF ASD TRIALS IN NEONATES
Ethical challenges in drug development for neonatal seizures
Neonates are uniquely vulnerable clinical research subjects. They
deserve special protection, but also deserve to be treated with
evidence-based therapies.12 The goal of protecting neonates from
the risks of research needs to be balanced with the goal of
protecting them from non-validated therapies.11,12 It is generally
agreed that children, including neonates, should be given
medicines that have been properly evaluated for their use in the
intended population.57
Drug trials are scientiﬁcally and ethically necessary to establish
the efﬁcacy and safety of drugs that are already widely used in
neonates as well as to develop new neonate-speciﬁc drugs that
have not been studied in other populations.58 Many challenges of
developing ASDs are similar to those for other types of drugs in
neonates. However, speciﬁc challenges of neonatal seizure trials
need to be considered:
A. The timing and nature of acute seizures requiring immedi-
ate treatment often allow little time for obtaining informed
consent from parent(s).
B. The underlying etiology of the seizures is usually unknown
at the time of enrollment or randomization.
C. Seizures are an unexpected medical emergency and are
often subclinical, hence the clinical urgency may be difﬁcult
for parents to understand.
D. There is a standard of care, namely phenobarbital as ﬁrst-
Table 1. Secondary outcome measures in the neonate
Criteria Description
Oral feeding ability Sufﬁcient infant bottle or breast feeding for growth, partial or total gavage feedings, gastrostomy feedings, or
intravenous nutrition required
Health Respiratory requirements, growth parameters especially head circumference, medications required
Hearing Neonatal hearing screening tests:
1. Auditory brainstem responses
2. Otoacoustic emissions
Vision Visual responses to stimuli
Neuroimaging Brain structural MR imaging with a central reader is preferred; its value as an outcome depends on the homogeneity
of conditions deﬁned for the trial, and ideally is obtained at approximately term age before NICU discharge (or by
44 weeks postmenstrual age)
Neonatal clinical assessmenta Four assessments are widely used in full-term neonates with brain injury:
1. Amiel-Tison Neurological Assessment at Termb (ATNAT)70,71: An exam with 4 outcome categories: Normal; Minor,
Moderate or Severe neurological abnormalities/CNS depression
2. Qualitative Assessments of General Movements (GMs): scoring based on observation of a neonate’s spontaneous
movements72,73
3. The Hammersmith Infant Neurological Examb (HINE):74,75 an exam that is scored based on calculation of an
optimality score
4. NICU Network Neurobehavioral Scale (NNNS):76 an exam that generates raw scores on 115 items converted to
13 summary scores
aAll require training to establish inter-rater reliability
bMeasures neurologic integrity and sensory responses and behavior that involve neurologic examination and observation of infant behavior
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line treatment,4 even though there is little evidence to
support its use.
E. Although animal data suggest that treatment of neonatal
seizure improves outcome, there is less evidence in human
newborns.1
F. Epilepsy carries societal stigma which may cause additional
parental anxiety.
Ethical considerations of trial design
The use of placebos in trials is controversial. Since there is a
standard treatment for neonatal seizures, it is usually unethical to
withhold that treatment, even if the evidence for the efﬁcacy of
the standard treatment is weak (e.g., phenobarbital).24,59 Guide-
lines from regulatory authorities in the US and the EU on the use
of placebos are clear.31,60 Given the expected sequelae of
untreated seizures, it would not be permissible to withhold
standard therapy, currently phenobarbital. It would be permissible
to compare any new ASD to phenobarbital. Placebos could be
used to evaluate a new ASD using an “add-on” method, keeping
the subjects on identical maintenance treatments with the
standard drug (e.g., phenobarbital), then adding treatment with
a new ASD to one arm and placebo to the other. This design could
also be used to test the initiation of treatment with a new ASD
Table 2. Secondary outcome measures of toddlers
Criteria Description
Post-neonatal onset epilepsy Specify seizure type according to ILAE77,78
Health 1. Hospitalizations and/or surgeries
2. Medical visits; therapies, other allied professional support, and medications
3. Growth percentiles for height, weight, and head circumference
4. Cardiorespiratory, e.g., limited exercise tolerance, need for respiratory support
5. Gastrointestinal, e.g., need for a special diet or parenteral nutrition, presence of a stoma or
gastrostomy
Neurosensory outcomes 1. Visual impairment
a. Visual acuity, e.g., total blindness (i.e., no light perception), severe visual impairment, use
of glasses
b. Cerebral visual impairment
2. Hearing impairment, including response to hearing aids or cochlear implant
a. Profound > 90 dB
b. Severe 70–90 dB
c. Moderate 40–70 dB
Neuromotor outcomes 1. Clinical neurological examination
a. Hammersmith Infant Neurological Examination (HINE)74,79: 2 to 24 months
b. Amiel-Tison Neurological Development from Birth to Six Years80: Birth to 6 years
2. Detailed assessment of motor performance
a. Gross Motor Function Measure (GMFM)81: 6 months to 18 years
b. Peabody Developmental Motor Scale, Second Edition (PDMS-2)82: Birth to 60 months
3. Diagnosis of cerebral palsy (CP) based on clinical examination and motor function scores, and
classiﬁed according to the Surveillance of Cerebral Palsy in Europe (SCPE) criteria83,84
4. In children with CP, the Gross Motor Function Classiﬁcation System (GMFCS) grades severity of
motor impairment into 5 levels.85,86
Neurocognitive and language outcomes 1. Difﬁculties in assessing cognition in infants and young children
a. Requires attention, some motor function (especially ﬁne motor) to perform tasks, and
receptive language to understand.
b. There are no established tools for assessment of children who have major sensory or
motor impairments.
c. At 2 years, there are no established assessment tools for more sophisticated cognitive functions
(e.g., executive functions, abstract reasoning) which are still developing.
2. Standardized measures of cognitive and language abilities have been used, but care is required in
their interpretation. Translations into many languages not available. Where possible, performance
may better be compared to that of typically developing children, although this may not be
practicable in the context of a trial. Where direct assessment is not possible, all available evidence
should be collected to categorize performance in standard deviation score bands.
a. Bayley Scales of Infant Development, Third Edition (BSID-III)87: 1 month to 42 months;
5 scales (cognitive, language, motor, social-emotional, and adaptive)
b. Grifﬁths Mental Development Scales, Third Edition (GMDS III)88: Birth to 72 months;
5 scales (foundations of learning, language and communication, eye and hand
coordination, personal and social-emotional, gross motor)
c. Mullen Scales of Early Learning89: Birth to 68 months; 5 scales (gross motor, ﬁne motor,
visual reception, receptive language, expressive language)
Combined adverse categorical neurodevelopmental
outcomes
1. By severity, e.g., British Association of Perinatal Medicine90
a. Severe
b. Moderate
c. Mild
2. For a dichotomous variable, generally children with moderate and severe impairment are
combined into a single group (children with neurodevelopmental impairment), with a 2nd group of
children with no or mild impairment.
Functional outcomes 1. Mobility, e.g., Gross Motor Classiﬁcation System
2. Communication: Difﬁcult to assess with standardized assessment tools when there are multiple
primary languages
3. Adaptive function: Ability to perform self-help skills (e.g., dressing/undressing, self-feeding)
4. Standardized measures of functional outcome
a. Pediatric Evaluation of Disability Inventory (PEDI)91: 6 months to 7.5 years; measures self-
care, mobility, and social function; targeted for children with disabilities
b. Vineland Adaptive Behavioral Scales, Second Edition (VABS-II)92: Birth to 90 years;
measures adaptive behavior
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(added on to phenobarbital) at different time points, by having
one arm in which the new ASD was started at a deﬁned Time Zero
and another arm in which the new ASD was started at some
designated later time. The rationale for the use of placebo must be
explained in lay language in the consent form and subjects should
be told that placebos are only used because of uncertainty
regarding whether the new agent is safer or more effective than
placebo.
Ethical considerations of methods of obtaining consent
The full written consent process has been successfully used in
many neonatal randomized controlled trials, even those requiring
consent within a short time window ( < 6 h, e.g., > 90% consent
rate in the original surfactant trial61,62 and therapeutic hypother-
mia for hypoxic-ischemic encephalopathy trial63). Full written
consent with parental signature should be obtained prior to
beginning any research trial of ASDs.64 However, neonatal seizures
are often both acute and unexpected and may necessitate a much
shorter time window during which the treatment should be
administered. Informed consent cannot be waived, but there is a
provision for exception from informed consent for emergency
research, which may be relevant for trials in speciﬁc conditions
such as status epilepticus in neonates.65–67
If parents are not available at the study site for in person consent,
the consent could be sent by fax or secure email or with the study
hospital’s transport team, reviewed with the study team by phone,
and returned by fax, secure email, or by an electronic consent form
on a secure website. In addition to obtaining written consent at
enrollment, implementation of a continuous consenting process
should be strongly considered.68 After enrollment, study team
members meet with the parents at regular intervals throughout the
intervention to ensure that they understand the trial procedures and
afﬁrm continued participation. This continuous consenting process
is important to supplement the often time pressured review of
written consent in neonatal seizure treatment trials.
Parent participation in ASD trials
Patient and public involvement is important, in particular
including parent representatives from parent associations in trial
design and implementation.69
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